Management to host conference call at 8:00 AM Eastern time on Friday, June 26, 2026
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise.
Company overview
Medexus is currently focused on delivering strong performance from GRAFAPEX, and also remains focused on supporting stable overall performance across the Company's portfolio of products in both the United States and Canada.
"Fiscal year 2026 represented an important transition point for Medexus," commented Ken d'Entremont, Chief Executive Officer of Medexus. "With the major portfolio evolution we have discussed in past quarters now largely reflected in our results, Medexus generated approximately $87.7 million of net revenue from our established portfolio excluding GRAFAPEX. Medexus enters fiscal year 2027 with a strong baseline that will highlight the growth of GRAFAPEX relative to the underlying strength and resilience of the rest of our portfolio. The continued momentum of GRAFAPEX and our ongoing business development initiatives focused on allo-HSCT will build on that foundation and position Medexus for sustained growth."
Key update on GRAFAPEX
Medexus has continued to see a positive market response to GRAFAPEX™ (treosulfan) for Injection since the US commercial launch of the product in February 2025. The Company expects GRAFAPEX will account for a significant portion of total net revenue and operating cash flow over the coming fiscal years. For the three- and twelve-month periods ended March 31, 2026, Medexus recognized product-level net revenue from GRAFAPEX of $3.4 million and $11.6 million, relative to $2.7 million and $11.2 million of GRAFAPEX personnel and infrastructure investments. Medexus continues to expect that annual product-level net revenue from GRAFAPEX will exceed $100 million within five years after commercial launch.
"Product-level performance for GRAFAPEX continues to demonstrate strong momentum, with sequential quarter-over-quarter growth of 50% in underlying patient demand in fiscal Q4 2026 compared to fiscal Q3 2026," Mr. d'Entremont continued. "We were pleased to see that Adjusted EBITDA* for fiscal year 2026 was positively affected by product-level net revenue from GRAFAPEX of $11.6 million exceeding the $11.2 million of GRAFAPEX personnel and infrastructure investments we made in the same period."